Patterson R, Harris K E, Lee M L, Houlihan W J
Int Arch Allergy Appl Immunol. 1986;81(3):265-8. doi: 10.1159/000234145.
Previous studies with synthetic platelet-activating factor (PAF) (AGEPC) showed that aerosol challenges in rhesus monkeys resulted in airway responses simulating acute antigen-induced responses and immediate-type skin reactions [1]. The current studies evaluated whether an antagonist of PAF (SRI 63-072) could inhibit the airway and cutaneous reactivity to PAF. Under the conditions of these experiments, the antagonist partially inhibited PAF activity in both experimental systems. Inhibition of endpoint cutaneous reactivity to PAF may be a suitable system for comparing potency of pharmacologic antagonists in primate skin.
先前对合成血小板激活因子（PAF）（1-烷基-2-乙酰基-sn-甘油-3-磷酸胆碱，AGEPC）的研究表明，对恒河猴进行气雾剂激发会导致气道反应，模拟急性抗原诱导的反应和速发型皮肤反应[1]。当前的研究评估了PAF拮抗剂（SRI 63-072）是否能够抑制气道和皮肤对PAF的反应性。在这些实验条件下，该拮抗剂在两个实验系统中均部分抑制了PAF活性。抑制对PAF的终点皮肤反应性可能是比较灵长类皮肤中药理拮抗剂效力的合适系统。
